Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Cancer Non-resectable: early-phase trial registry
3 of 5 indexed Pancreatic Cancer Non-resectable trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Pancreatic Cancer Non-resectable: 5 US clinical trials tracked, 3 recruiting.
Pancreatic Cancer Non-resectable is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Englewood Hospital and Medical Center, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-cancer-non-resectable
OPEN 3 | RECR 60% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)
Pancreatic Cancer Non-resectable lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Cancer Non-resectable on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Cancer Non-resectable is recruiting above its size-band peers.
3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Pancreatic Cancer Non-resectable research.
Englewood Hospital and Medical Center accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Cancer Non-resectable trials plan to enrol fewer than 100 people.
Median target enrolment is 25 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Pancreatic Cancer Non-resectable research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
HealthPartners Institute
NCT06605430
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
NCT03977233
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
Englewood Hospital and Medical Center
NCT06937996
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Memorial Sloan Kettering Cancer Center
NCT05642962
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT04116073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Cancer Non-resectable records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Cancer Non-resectable trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Cancer Non-resectable page
5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Pancreatic Cancer Non-resectable trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Englewood Hospital and Medical Center sponsors the most Pancreatic Cancer Non-resectable trials on record, review their full trial history before evaluating a specific study. See Englewood Hospital and Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Cancer Non-resectable condition card totals 5 registered trials; most-linked intervention INCMGA00012 (PD-1 antibody); top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.